One of the biggest problems with the accepted stratification of DLBCL is the disparity in treatment response even in the presence of seemingly identical focal mutations in both ABC and GCB, such as TP53 deletion or MYC mutations (Jia et al., 2012; Xu-Monette et al., 2012; Cao et al., 2016; Xu-Monette et al., 2016). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.